EGFR and cancer: The approach of inhibiting IGF1R with a small molecule is validated by the numerous receptor tyrosine kinases (RTKs) that have been effectively targeted in the treatment of cancer, including Bcr-Abl (imatinib), EGFR (erlotinib, gefitinib) and EGFR/ErbB2 (lapatinib).